~~<i id='C27A369E46'><strike id='C27A369E46'><tt id='C27A369E46'><pre id='C27A369E46'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：entertainment 2025-09-30 22:10:41 - browse：181

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

focus

knowledge

hotspot

PascalSoriothasservedasCEOofAstraZenecasince2012.WinMcNamee/GettyImagesCAMBRIDGE,England—Onabitofaro

WSS

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Bird flu surveillance in wastewater gets boost from consortium

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

explore

explore

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

After affirmative action ruling, medical educators look to 'holistic review'

For longer

Cancer drug shortages should be causing more outrage

Fentanyl is making it harder to start addiction treatment

Wildfire smoke exposes gaps in outdoor worker protections

Listen: A conversation with researcher Kevin Esvelt on biosecurity

knowledge

Fentanyl is making it harder to start addiction treatment

Study finds gene variants tied to breast cancer risk in Black women

UnitedHealth argues against case alleging wrongful AI care denials

Scrutiny of post

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

FDA poised to publish guidelines for clinical trial diversity

knowledge

hotspot

hotspot

hotspot